ERBB2 and cancer: In addition, a significant number of patients with HER2-positive cancer are either intrinsically resistant or eventually acquire resistance to anti-HER2-based therapy with trastuzumab, which is a major monoclonal antibody used to clinically treat HER2-positive cancer [6].